Glenmark Pharmaceuticals Ltd.
Industry Group: Pharmaceuticals
Country/Region: India
Identifier: BOM:532296
Glenmark Pharmaceuticals Ltd is a specialty and generic drug manufacturing company. The company's research and development activity is focused on generating intellectual property assets that will help address unmet medical needs. Glenmark's product categories include novel molecular entities, formulations, and API products. The company considers merger and acquisition investment to be a potential component for expanding its research, development, manufacturing, and marketing capabilities.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 640 out of 922
Universe
Global Universe 12667 out of 16179
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
Company | ESG Risk Rating | Industry Rank |
---|---|---|
Santen Pharmaceutical Co., Ltd. |
27.2
Medium
|
347 out of 922 |
Prestige Consumer Healthcare, Inc. |
29.9
Medium
|
521 out of 922 |
Hypera SA |
32.1
High
|
626 out of 922 |
Glenmark Pharmaceuticals Ltd. |
32.4
High
|
640 out of 922 |
China National Medicines Co., Ltd. |
39
High
|
874 out of 922 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Glenmark Pharmaceuticals Ltd.'s Exposure is Medium
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Glenmark Pharmaceuticals Ltd.'s Management of ESG Material Risk is Average
How do the ESG Risk Ratings work?
Controversy Rating
Highest Controversy level that has impacted Glenmark Pharmaceuticals Ltd.'s ESG Risk Rating in the last three years
Highest Controversy Level